|
| |
Neurobiological TechnologiesNeurobiological Technologies, Inc. (NTI) (NASDAQ: NTII) is a biotechnology company engaged in the business of acquiring and developing central nervous system (CNS) related drug candidates. The company is focused on therapies for neurological conditions that occur in connection with dementia, Alzheimer's disease, ischemic stroke, neuropathic pain, and brain cancer.
The company employs a strategy of in-licensing late-stage CNS agents and pursues regulatory approval and commercialization either independently or with a strategic partner.
| Contact Details: |
| 2000 Powell Street, Suite 800 |
| Emeryville |
| California |
| 94608 |
| United States of America |
| Tel: | (510) 595-6000 |
| Fax: | (510) 595-6006 |
| Email: | careers@ntii.com |
| WWW: | www.ntii.com/
|
|
Loading...
|
Recent Publications by Neurobiological Technologies: |  |
Clinical trials, devices, unproven treatments, and clinical equipoise.
We have chosen to use the filamentous fungus Neurospora crassa to produce... | 13th June, 2009
| Neurobiological Technologies, Inc, 2000 Powell St, Suite 800, Emeryville,
| Stroke. 2009 Jun;40(6):e441-2. Epub 2009 May 7.
DOI Direct Link |
Ancrod for acute ischemic stroke: a new dosing regimen derived from analysis of prior ancrod stroke studies.
BACKGROUND: Ancrod, a fibrinogen-reducing agent, has been evaluated as... | 6th February, 2009
| Neurobiological Technologies Inc, Edgewater, New Jersey 07020, USA.
| J Stroke Cerebrovasc Dis. 2009 Jan;18(1):23-7.
DOI Direct Link |
Press Releases on Neurobiological Technologies:
|
 |
| Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share |
23rd November, 2009 |
Neurobiological Technologies, Inc. |
EMERYVILLE, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) ("NTI") announced today that its board of directors has declared an extraordinary
|
| Neurobiological Technologies Announces Stockholder Approval of Plan of Liquidation and Dissolution |
28th October, 2009 |
Neurobiological Technologies, Inc. |
EMERYVILLE, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) ("NTI") announced today that its stockholders have voted in favor of the company&apos
|
| Neurobiological Technologies Announces Intent to File Form 25 to Delist Common Stock From the NASDAQ Capital Market |
19th October, 2009 |
Neurobiological Technologies, Inc. |
EMERYVILLE, Calif., Oct. 19 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) ("NTI") announced today it has submitted written notice to the NASDAQ Stock Market LLC
|
| Neurobiological Technologies' Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program |
1st June, 2009 |
Neurobiological Technologies, Inc. |
EMERYVILLE, Calif., June 1 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) (NTI(R)) today announced that Celtic Pharmaceutical Holdings L.P. (Celtic Pharma) has announced
|
| Neurobiological Technologies Reports Third Quarter Fiscal 2009 Financial Results |
8th May, 2009 |
Neurobiological Technologies, Inc. |
EMERYVILLE, Calif., May 8 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced financial results for the three-month and nine-month periods ended March
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 382 times since April 2007, the link to the organisation's website has been followed 78 times Search for more companies in Emeryville Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Neurobiological Technologies |
